Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic hepatitis B: a critical appraisal of current approaches to therapy.
Perrillo RP, Gish RG, Peters M, Keeffe EB, Alberti A, Buti M, Cooksley WG, Fried MW, Hadziyannis SJ, Liaw YF, Naoumov NV, Schiff ER, Thio CL, Tsai N, Schalm S. Perrillo RP, et al. Among authors: schiff er. Clin Gastroenterol Hepatol. 2006 Feb;4(2):233-48. doi: 10.1016/s1542-3565(05)00983-3. Clin Gastroenterol Hepatol. 2006. PMID: 16469685
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Perrillo RP, et al. Among authors: schiff er. Hepatology. 2002 Jul;36(1):186-94. doi: 10.1053/jhep.2002.34294. Hepatology. 2002. PMID: 12085364 Clinical Trial.
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG; BEHoLD Study Group. Chang TT, et al. Among authors: schiff er. Gastroenterology. 2005 Oct;129(4):1198-209. doi: 10.1053/j.gastro.2005.06.055. Gastroenterology. 2005. PMID: 16230074 Clinical Trial.
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.
Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, de Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA; International Lamivudine Investigator Group. Schiff ER, et al. J Hepatol. 2003 Jun;38(6):818-26. doi: 10.1016/s0168-8278(03)00076-x. J Hepatol. 2003. PMID: 12763376 Clinical Trial.
411 results